Skip to main content
Top

2011 | OriginalPaper | Hoofdstuk

22. Maligne tumoren van de weke delen

Auteurs : Prof. dr. W. T. A. van der Graaf, Dr. J. V. M. G. Bovée, Dr. R. L. M. Haas, Prof. dr. H. J. Hoekstra

Gepubliceerd in: Oncologie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Wekedelensarcomen vormen een heterogene groep mesenchymale maligniteiten. Van het totale aantal maligniteiten op volwassen leeftijd maken ze circa 1% uit, van de kindertumoren 8%. Jaarlijks wordt in Nederland bij ongeveer 1000 volwassenen en 40 kinderen de diagnose wekedelensarcoom gesteld. De presentatie en de lokalisatie zijn zeer divers, maar ook de variatie in histologische (sub)typen is groot. Wekedelentumoren worden onderverdeeld volgens de WHO-classificatie in 33 histologische (sub)typen. Benigne wekedelentumoren komen veel vaker voor dan maligne mesenchymale tumoren. Hooggradige wekedelensarcomen metastaseren in circa 40-50% van de gevallen, veelal binnen twee tot vijf jaar na diagnose. Metastasering vindt voornamelijk hematogeen plaats, meestal pulmonaal, minder vaak naar botten of lever. In minder dan 5% van de gevallen treedt lymfogene metastasering op. Ongeveer 10% van de patiënten presenteert zich met al gemetastaseerde ziekte. Behandeling bestaat waar mogelijk uit radicale chirurgische resectie, zo nodig gevolgd door radiotherapie. Op een enkele uitzondering na is er voor chemotherapie geen indicatie bij de primaire behandeling van het wekedelensarcoom. Sinds 2001 hebben gastro-intestinale stromatumoren een bijzondere plaats binnen de groep van de wekedelensarcomen verworven door de introductie van behandeling met de selectieve tyrosinekinaseremmer imatinib.
Literatuur
go back to reference Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101.CrossRefPubMed Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101.CrossRefPubMed
go back to reference Bossi A, Wever I de, Limbergen E van, Vanstraelen B. Intensity modulated radiation-therapy for preoperative posterior abdominal wall irradiation of retroperitoneal liposarcomas. Int J Radiat Oncol Biol Phys 2007;67:164-70.CrossRefPubMed Bossi A, Wever I de, Limbergen E van, Vanstraelen B. Intensity modulated radiation-therapy for preoperative posterior abdominal wall irradiation of retroperitoneal liposarcomas. Int J Radiat Oncol Biol Phys 2007;67:164-70.CrossRefPubMed
go back to reference Casali PG, Blay JY. ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 (Suppl 5);v98-102.CrossRef Casali PG, Blay JY. ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 (Suppl 5);v98-102.CrossRef
go back to reference Davis AM, O’Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel RA, Sadura A, Day A, James K, Tu D, Pater J, Zee B. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:4472-7.CrossRefPubMed Davis AM, O’Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel RA, Sadura A, Day A, James K, Tu D, Pater J, Zee B. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:4472-7.CrossRefPubMed
go back to reference Demetri GD, Mehren M von, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.CrossRefPubMed Demetri GD, Mehren M von, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.CrossRefPubMed
go back to reference Enzinger FM, Weiss SW. Soft tissue tumors. 5th ed. St Louis: Mosby, 2007. Enzinger FM, Weiss SW. Soft tissue tumors. 5th ed. St Louis: Mosby, 2007.
go back to reference Ginkel RJ van, Thijssens KM, Pras E, Graaf WT van der, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol 2007;14:1499-506.CrossRefPubMedPubMedCentral Ginkel RJ van, Thijssens KM, Pras E, Graaf WT van der, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol 2007;14:1499-506.CrossRefPubMedPubMedCentral
go back to reference Glabbeke M van, Oosterom AT van, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Study. J Clin Oncol 1999;17:150-7.CrossRefPubMed Glabbeke M van, Oosterom AT van, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Study. J Clin Oncol 1999;17:150-7.CrossRefPubMed
go back to reference Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15(1):350-62.CrossRefPubMed Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15(1):350-62.CrossRefPubMed
go back to reference Hogendoorn PC. ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 (Suppl 5);v204-13.CrossRef Hogendoorn PC. ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 (Suppl 5);v204-13.CrossRef
go back to reference Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-7.CrossRefPubMed Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-7.CrossRefPubMed
go back to reference Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54.CrossRef Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54.CrossRef
go back to reference Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, Oosterom A van, Hogendoorn PC, Glabbeke M van, Bertulli R, Judson I . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.CrossRefPubMed Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, Oosterom A van, Hogendoorn PC, Glabbeke M van, Bertulli R, Judson I . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.CrossRefPubMed
go back to reference World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002. World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002.
Metagegevens
Titel
Maligne tumoren van de weke delen
Auteurs
Prof. dr. W. T. A. van der Graaf
Dr. J. V. M. G. Bovée
Dr. R. L. M. Haas
Prof. dr. H. J. Hoekstra
Copyright
2011
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8476-1_22